IMMUCELL CORP /DE/ (ICCC) Form 8-K — Oct 13, 2026
ImmuCell Corporation announced preliminary, unaudited Q3 2026 sales of $8.0 million, up 46.0% year over year, with domestic sales of $6.9 million, up 29.2%. Growth was broad-based: Tri-Shield grew 51%, Dual-Force 36%, and the recently launched functional feed line 37%, aided by an expanded sales team and improved manufacturing reliability.
Key figures
- Revenue
- 8000000
- Revenue Yoy
- 46.0%
- Dualforce growth
- 36%
- Nine month sales
- $25.6 million
- Trishield growth
- 51%
- Domestic sales q3
- $6.9 million
- Nine month growth
- 27.8%
- Domestic sales growth
- 29.2%
- Functional feed growth
- 37%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.